Immunotherapy, The Most Prominent Topic In Skin Cancer Research
Immunotherapy, treatment of cancer with substances that strengthen the body's natural immune response, is the most prominent topic within melanoma research, accounting for 4.9 percent of papers published between 2013 and 2018.
Findings in the report highlight that melanoma research accounted for 4-5 percent of all cancer research output globally over the past two decades, with just under 50,000 melanoma research papers published between 2013 and 2018, suggesting more research can be done.
Immunotherapy, treatment of cancer with substances that strengthen the body's natural immune response, is the most prominent topic within melanoma research, accounting for 4.9 percent of papers published between 2013 and 2018. Specifically, research has centred around newly developed immunotherapies, such as nivolumab, ipilimumab and lambrolizumab. The top 10 immunotherapy papers include research on both monotherapies, or single-drug therapies, and drug combinations.
Further findings highlighted in the report
Of the top 10 countries by research output in melanoma research:
· Five were European (Germany, Italy, UK, France and Spain), collectively accounting for 15,688 papers published.
· When research is compared to the rate of melanoma at a country level, only Australia and Germany from the top 10 countries in terms of melanoma rates are also in the top 10 most active countries engaging in melanoma research.
· Northern and Central European countries are among some of the most common places where melanoma is diagnosed, however, they did not appear in the top 10 list of countries engaged in the research of the cancer.
Top 10 countries by scholarly output in melanoma research (2013-2018)
1. United States
5. United Kingdom
As this report shows, melanoma is a significant focus of academic research globally, and while it is clear that patients are benefiting from the latest research into novel therapies to treat melanoma, there are gaps that need to be addressed with more research.
Biochempeg, a professional PEG derivatives supplier supplies PEG linkers, monodisperse PEG, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide. It offers a selection of PEG derivatives for cancer research including melanoma research, breast cancer research, diabetes research and so on.
Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
Biochempeg Scientific Inc.